Nonclinical precedent Request an invite
Species
Cynomolgus monkey only
“Overall, data indicate that linvoseltamab bound human and Cynomolgus monkey BCMA, but not rat or mouse BCMA.”
✓ VerifiedEMA assessment report, p. 27Source ↗
Why that species
Binds human and monkey BCMA (monkey lower affinity, KD 24.6 nM vs 437 pM human) and CD3 on both; no rat/mouse BCMA binding
“Overall, data indicate that linvoseltamab bound human and Cynomolgus monkey BCMA, but not rat or mouse BCMA.”
✓ VerifiedEMA assessment report, p. 27Source ↗
Surrogate molecule
No surrogate; clinical molecule (REGN5458) tested in cynomolgus monkey
“Two repeat dose toxicology studies were performed by the applicant, (Study R5458-TX-17179 and Study r5458-tx-20118).”
✓ VerifiedEMA assessment report, p. 31Source ↗
Species: general tox
Cynomolgus monkey only
“The first study was conducted in male and female monkeys once weekly for 5 weeks at doses of 0.1, 1, or 10 mg/kg IV infusion with a subsequent recovery period of 12.”
✓ VerifiedEMA assessment report, p. 36Source ↗
Species: DART
Not conducted (weight-of-evidence risk assessment)
“No animal reproductive or developmental toxicity studies have been conducted with linvoseltamab.”
✓ VerifiedEMA assessment report, p. 37Source ↗
Species: carcinogenicity
Not conducted (ICH S9, advanced malignancies)
“As linvoseltamab is intended for use in patients with advanced malignancies, carcinogenicity studies were not conducted with linvoseltamab, consistent with ICH S9 guideline Nonclinical Evaluation of Anticancer Pharmaceuticals.”
✓ VerifiedEMA assessment report, p. 33Source ↗
Surrogate used in
No surrogate used; clinical molecule tested in cynomolgus monkey
“Safety pharmacology evaluations were integrated into a GLP-compliant repeat-dose toxicology study conducted in Cynomolgus monkeys using linvoseltamab”
✓ VerifiedEMA assessment report, p. 29Source ↗

Same question, other multispecifics

Bizengri

zenocutuzumab · HER2 x HER3
Cynomolgus monkey only

Blincyto

blinatumomab · CD19 x CD3
Chimpanzee (only relevant species, limited non-terminal studies) plus mouse with murine surrogate

Columvi

glofitamab · CD20 x CD3
Cynomolgus monkey only

Elrexfio

elranatamab · BCMA x CD3
Cynomolgus monkey only

Epkinly

epcoritamab · CD20 x CD3
Cynomolgus monkey only

Hemlibra

emicizumab · FIXa x FX
Cynomolgus monkey only

Imdelltra

tarlatamab · DLL3 x CD3
Cynomolgus monkey (pivotal); mouse surrogate muS757 for EFD and 1-month study

Kimmtrak

tebentafusp · CD3 x gp100 (TCR fusion)
No relevant species; in vitro human cell/tissue assays only

Korjuny

catumaxomab · EpCAM x CD3
No relevant species; limited single-dose mouse, rat, one cynomolgus; BiLu mouse surrogate

Lunsumio

mosunetuzumab · CD20 x CD3
Cynomolgus monkey only

Ordspono

odronextamab · CD20 x CD3
Cynomolgus monkey only

Removab

catumaxomab · EpCAM x CD3
No relevant species; in vitro human cells plus mouse surrogate (BiLu); limited single-dose rodent/monkey

Rybrevant

amivantamab · EGFR x MET
Cynomolgus monkey only

Talvey

talquetamab · GPRC5D x CD3
Cynomolgus monkey only (tool molecule for pivotal tox); no rodent tox

Tecvayli

teclistamab · BCMA x CD3
Cynomolgus monkey only (rabbit used for SC local tolerance only)

Vabysmo

faricimab · VEGF-A x Ang-2
Cynomolgus monkey only for pivotal tox (rabbit dropped after early studies)

Ziihera

zanidatamab · HER2 x HER2 (biparatopic)
Cynomolgus monkey only

Summary across all 18 multispecifics →